Neurontin Fraudulent Marketing Class Action

TBS  represented a national class  of insurance providers alleging that in an effort to boost profits, Pfizer, Inc. and Warner-Lambert Co. sold the drug Neurontin for uses for which it was neither approved by the U.S. Food and Drug Administration nor medically effective.  Pfizer Inc. agreed to pay $325 million to resolve the class’s claim that Pfizer defrauded insurers and other healthcare benefit providers by its off label marketing of Neurontin.